So here's something interesting I've been thinking about in the pharma space lately. Eli Lilly absolutely crushed it with their GLP-1 drugs in 2025 - Mounjaro and Zepbound grew sales by 99% and 175% respectively. Pretty wild numbers. But here's the thing that's got me pausing: the market might be getting a little too euphoric about this one.

Lilly's whole 45% sales growth last year basically came down to these two drugs. Now they account for 56% of the company's entire revenue. That's a lot of eggs in one basket, and when those patents eventually expire, there's going to be a serious revenue gap to fill. Meanwhile, the stock is trading at a 44 P/E with a dividend yield of just 0.6%. That's what I'd call priced for absolute perfection.

What's interesting to me is that everyone's sleeping on the competitors. Novo Nordisk was actually first to market with GLP-1 drugs but lost ground to Lilly - their drugs just seem to work better right now. But they just launched an oral GLP-1 option, which is a meaningful move. They've also got a massive diabetes business supporting them. The yield is sitting at 4.9% and the P/E is only 10. That's a completely different valuation story.

Pfizer's in a trickier spot - they had to kill their own GLP-1 program and bought into a biotech candidate instead. Higher risk there. But they've got decades of pharma credibility and they're exploring migraine and oncology plays too. The yield is 6.3% because of upcoming patent cliffs, and yeah, their payout ratio is over 100%, but management says they're committed to maintaining the dividend. P/E around 20.

The way I see it, the drug space is brutally competitive and driven by innovation. Novo Nordisk and Pfizer have proven track records as serious competitors. So while Eli Lilly's got the momentum right now, those other two probably won't stay on the sidelines forever. Worth keeping an eye on if you're looking at this sector.